Results 141 to 150 of about 399,367 (396)

Clonal karyotype evolution involving ring chromosome 1 with myelodysplastic syndrome subtype RAEB-t progressing into acute leukemia [PDF]

, 2006
s Karyotypic evolution is a well-known phenomenon in patients with malignant hernatological disorders during disease progression. We describe a 50-year-old male patient who had originally presented with pancytopenia in October 1992.
Bennett JM, Bettina Wunderlich, Brigitte Poleck-Dehlin, Chen Z, Christoph Schmid, Cutler CS, De Witte T, Depil S, Georg Ledderose, Gisselsson D, Gullingsrud EO, Hans Jochen Kolb, Hebart H, Helga Schmetzer, Hoffmann WK, Hoffmeister PA, Holler E, Johann Mittermüller, Johansson B, Jotterand M, Kern W, Kolb HJ, Kolb HJ, Massenkeil G, Mattano, Mhawesch P, Mittermuller J, Moss PA, Mufti GJ, Rothe G, Sanders JE, Schmetzer H, Schmetzer H, Schmetzer HM, Schmid C, Seabright M, Seber A, Slovak ML, Sole F, Sole F, Thomas Duell, Tichelli A, Tichelli A, van Esser JW, Xu J, Yan J, Yoshida A   +46 more
core   +1 more source

The impact of introducing tyrosine kinase inhibitors on chronic myeloid leukemia survival: a population-based study

BMC Cancer, 2018
Background Chronic myeloid leukemia is associated with a BCR/ABL oncoprotein inhibited by imatinib mesylate, the first tyrosine kinase inhibitor. Although experimental studies have clearly demonstrated the efficacy of imatinib, up-to-date data on its ...
Enza Di Felice, Francesca Roncaglia, Francesco Venturelli, Lucia Mangone, Stefano Luminari, Claudia Cirilli, Giuliano Carrozzi, Paolo Giorgi Rossi   +7 more
doaj   +1 more source

Fast pH‐Driven Solubilization Method of Realgar (As4S4) to Reduce the Toxicity of Arsenic [As(III)] for Medicinal Purposes

Advanced Science, EarlyView.
Arsenic trioxide transformed acute promyelocytic leukemia therapy and shows promise against HIV. A new method to solubilize the mineral realgar produces different arsenic species depleting the main arsenic target, nuclear PML protein, and retaining effects on leukemic and HIV reservoir cells, while minimizing off‐target damage.
Bojana Lucic, Douglas Santana Franciscato, Helton Pereira Nogueira, Lara Gallucci, Alceu Totti Silveira Junior, Asmaa Mohamed Ismail, Millie Robinson, Teresa Dallinger, Claudia Gutfleisch, Jochen Kurz, Maytê Toledo, Jessica Dias da Silva Ferraz, Mohammad Tarek, Danilo Dias, Ricardo Sobhie Diaz, Mahmoud ElHefnawi, Mattia Forcato, Hugo P Monteiro, Marina Lusic, Iart Luca Shytaj, Andrea Savarino   +20 more
wiley   +1 more source

Role of the bone morphogenic protein pathway in developmental haemopoiesis and leukaemogenesis [PDF]

, 2016
Myeloid leukaemias share the common characteristics of being stem cell-derived clonal diseases, characterised by excessive proliferation of one or more myeloid lineage.
Toofan, Parto, Wheadon, Helen
core   +1 more source

Unusual Presentation of Priapism Associated with Acute and Chronic Myeloid Leukemia in Two Patients: Emergency Management

Case Reports in Urology, 2020
Priapism is a rare urological emergency. It is rarely a telltale sign of myeloid leukemia. We report two cases of acute myeloid leukemia in a child and chronic myeloid leukemia in a young adult presenting with priapism. Puncture irrigation of the corpora
Oumar Gaye, Ngor Mack Thiam, Ayun Cassell, Serigne Mourtalla Gueye, Yaya Sow, Boubacar Fall, Alain Khassim Ndoye   +6 more
doaj   +1 more source

Mitochondrial Regulation of CD8⁺ T Cells: Mechanisms and Therapeutic Modulation

Advanced Science, EarlyView.
This article comprehensively explores the pivotal role of mitochondrial function in CD8⁺ T cell immunotherapy. It highlights how mitochondrial dynamics regulate T cell activation, differentiation, and persistence, and how mitochondrial dysfunction leads to immune exhaustion and impaired antitumor/antiviral responses.
Xu Chen, Pei Lin, Ye Lu, Jiarong Zheng, Yunfan Lin, Zihao Zhou, Li Cui, Xinyuan Zhao   +7 more
wiley   +1 more source

Inhibition of MDR1 does not sensitize primitive chronic myeloid leukemia CD34⁺ cells to imatinib [PDF]

, 2009
<p><b>Objective:</b> To investigate the interaction of imatinib mesylate (IM) with the clinically relevant adenosine triphosphate-binding cassette efflux transporter MDR1 (ABCB1) in cells from patients with chronic myeloid leukemia (CML)
Hatziieremia, S., Holyoake, T.L., Jordanides, N.E., Jorgensen, H.G., Mountford, J.C.   +4 more
core   +1 more source

Co-operating STAT5 and AKT signaling pathways in chronic myeloid leukemia and mastocytosis: possible new targets of therapy

Haematologica, 2014
Chronic myeloid leukemia and systemic mastocytosis are myeloid neoplasms sharing a number of pathogenetic and clinical features. In both conditions, an aberrantly activated oncoprotein with tyrosine kinase activity, namely BCR-ABL1 in chronic myeloid ...
Siham Bibi, Melis Dilara Arslanhan, Florent Langenfeld, Sylvie Jeanningros, Sabine Cerny-Reiterer, Emir Hadzijusufovic, Luba Tchertanov, Richard Moriggl, Peter Valent, Michel Arock   +9 more
doaj   +1 more source

Complex cytogenetic abnormalities in chronic myeloid leukemia resulting in early progression to blast crisis: a case report

Journal of Medical Case Reports, 2020
Introduction BCR-ABL1, resulting from t(9;22), is the oncogenic driver of chronic myeloid leukemia and the therapeutic target of the disease. Molecular studies have been the gold standard modality for patient assessment since the advent of tyrosine ...
Haider Ali Malakzai, Soma Rahmani, Ahmed Maseh Haidary, Sarah Noor, Maryam Ahmad, Abdul Sami Ibrahimkhil, Samuel Sharif   +6 more
doaj   +1 more source

Immune Effector Recovery in Chronic Myeloid Leukemia and Treatment-Free Remission

Frontiers in Immunology, 2017
Chronic myeloid leukemia (CML) is a hematological cancer, characterized by a reciprocal chromosomal translocation between chromosomes 9 and 22 [t(9;22)], producing the Bcr-Abl oncogene. Tyrosine kinase inhibitors (TKIs) represent the standard of care for
Amy Hughes, A. Yong
semanticscholar   +1 more source